Nurix Therapeutics Inc

NASDAQ:NRIX

13.59

-0.85 (-5.89%)

5:59:36 PM EDT: $13.51 -0.08 (-0.59%)

Market Cap (Intraday)	806.09M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$21.78 Million
Adjusted EPS	-$0.69

See more estimates

10-Day MA	$14.75
50-Day MA	$13.08
200-Day MA	$9.34

See more pivots

Nurix Therapeutics Inc Stock, NASDAQ:NRIX

1700 Owens Street, Suite 205, San Francisco, California 94158

United States of America

Phone: +1.415.660.5320

Number of Employees: 284

http://www.nurixtx.com

Description

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael RapÃ?Â©, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.